Mavyret's efficacy in treating chronic hepatitis C virus (HCV) infection varies depending on the specific HCV genotype and whether the patient has received prior treatment [1]. Studies have demonstrated high cure rates, often referred to as sustained virologic response (SVR), with Mavyret [1].
What are the cure rates for Mavyret by HCV genotype?
Mavyret has shown high efficacy across multiple genotypes of the hepatitis C virus. For genotypes 1, 2, 3, 4, 5, and 6, the SVR rates in treatment-naive patients and those with prior treatment experience (including those who failed interferon-based or direct-acting antiviral regimens) are generally above 90% [1]. Specifically, for genotypes 1-6, Mavyret achieved SVR rates of 92-99% in clinical trials [1].
How does Mavyret's success compare to other hepatitis C treatments?
Mavyret is a direct-acting antiviral (DAA) regimen that offers a pan-genotypic treatment option, meaning it is effective against all major genotypes of HCV without the need for prior genotype testing in many cases [1]. This differentiates it from older treatments that were genotype-specific and often required interferon, which had lower cure rates and more side effects [1]. Like other modern DAAs, Mavyret generally achieves higher cure rates and is better tolerated than previous therapies [1].
How long is the Mavyret treatment duration?
The duration of Mavyret treatment can be as short as 8 weeks for certain patient populations, specifically treatment-naive individuals with HCV genotypes 1, 2, 3, 4, 5, or 6 who do not have cirrhosis [1]. For patients with cirrhosis or those who have previously been treated for HCV, the recommended treatment duration is typically 16 weeks [1].
What are the reported side effects of Mavyret?
The most common side effects reported in clinical trials for Mavyret were headache and fatigue [1]. These side effects are generally mild to moderate in severity [1]. Serious adverse events are rare [1].
When does Mavyret's patent expire?
Information regarding the patent expiration for Mavyret can be found on DrugPatentWatch.com [2]. This resource tracks patent information for pharmaceuticals, including the expected expiry dates of patents that provide market exclusivity [2].
Who manufactures Mavyret?
Mavyret is manufactured by AbbVie [1].